Joe Simpson
Genentech
4 Papers
41 Citations
Joe Simpson is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Performance status. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Guru Sonpavde,Gregory R. Pond,Jonathan E. Rosenberg,Toni K. Choueiri,Joaquim Bellmunt,Ashley Marie Regazzi,Stephanie A. Mullane,Andrea Necchi,Daniele Raggi,Jae-Lyun Lee,Soon Il Lee,Joe Simpson,Christina Louise Derleth,Shih-Wen Lin,Dean F. Bajorin +14 more
TL;DR: This nomogram may be a useful tool to interpret results of nonrandomized phase 2 trials of salvage therapy for metastatic urothelial carcinoma by assessing the OS contributions of drug intervention independent of prognostic variables.
16
Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies
Rebecca A. Moss,John Bothos,Premal Patel,Amy C. Peterson,Steve Eppler,Shuang Bai,Ihsan Nijem,Luc Desnoyers,Surinder Kaur,Jiping Zha,Wei Yu,Joe Simpson,Mark J. Ratain,Antoinette R. Tan,Mark N. Stein,Janice M. Mehnert,Ravi Salgia +16 more
TL;DR: MetMAb, when administered as a single-agent, or in combination with bevacizumab was generally well tolerated, both alone and in combination and the most frequent treatment-related adverse events included: fatigue, peripheral edema and hypoalbuminemia.
13
Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.
A. Vashishtha,Premal Patel,Wei Yu,J. G. Bothos,Joe Simpson,T. Maneatis,L. Doessegger,Amy C. Peterson,Christelle Clément-Duchêne,Gilles Robinet,Maciej Krzakowski,George R. Blumenschein,J. Goldschmidt,Davey B. Daniel,David R. Spigel +14 more
TL;DR: The combination of M+E did not substantially alter the safety profile of erlotinib and differences in AEs do not clearly explain the PFS and OS outcomes observed in Met Dx subgroups on M-E.
11
Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.
Gregory R. Pond,Guru Sonpavde,Jonathan E. Rosenberg,Toni K. Choueiri,Joaquim Bellmunt,Ashley Marie Regazzi,Stephanie A. Mullane,Andrea Necchi,Daniele Raggi,Jae-Lyun Lee,Soon Il Lee,Joe Simpson,Christina Louise Derleth,Shih-Wen Lin,Dean F. Bajorin +14 more
TL;DR: A nomogram was developed using prognostic variables from phase 2 trials of historical agents to estimate 12 month survival to which observed survival in single arm trials could be compared.
3